Header
For Healthcare Professionals

Achieving optimal T2D management while considering potential future kidney function decline

Prof Merlin Thomas

Prof Merlin Thomas

Related contents

What are the evidence of Trajenta (Linagliptin) in patients with type 2 dia.png.png
J.M Co, Prof Cooper

What are the evidence of  Trajenta (Linagliptin) in patients with type 2 diabetes and across different kidney profile or renal dysfunction?

  • 1.1.2023
whats next for dpp4i now that there are different agents out there is there still a role for dpp4i.png
J.M Co, Prof Cooper

What’s next for DPP4i, now that there are different agents out there? Is there still a role for DPP4i?

  • 1.1.2023
What are the evidences of Trajenta (linagliptin) in delaying the need for insulin among type 2 diabetes patients?
J.M Co, Prof Cooper

What are the evidences of  Trajenta (linagliptin) in delaying the need for insulin among type 2 diabetes patients?

  • 1.1.2023